🇺🇸 FDA
Patent

US 11771671

Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction

granted A61KA61K31/196A61P

Quick answer

US patent 11771671 (Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction) held by OVID THERAPEUTICS INC. expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
OVID THERAPEUTICS INC.
Grant date
Tue Oct 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/196, A61P, A61P27/16